Last reviewed · How we verify
Elemental Iron (As Carbonyl Iron) (Iron)
Elemental Iron (As Carbonyl Iron) is a small molecule iron drug developed by Hippocration General Hospital and currently owned by Allergan. It is used to treat various forms of anemia, including anemia of prematurity, iron deficiency anemia, and megaloblastic anemia due to folate deficiency. The commercial status of Elemental Iron is off-patent, with no active Orange Book patents. Key safety considerations include the potential for gastrointestinal side effects. It is used to replenish iron stores in the body.
At a glance
| Generic name | Iron |
|---|---|
| Also known as | oral iron, Ferretab, Ferli-6 (ferrous fumarate 200 mg, folic acid 0.5 mg, B6 5 mg), No other name, Noripurum |
| Sponsor | Hippocration General Hospital |
| Drug class | Vitamin C [EPC] |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
- Anemia of prematurity
- Iron deficiency anemia
- Magnetic resonance imaging of liver
- Megaloblastic anemia due to folate deficiency
Common side effects
- Blood iron decreased
- Colitis ulcerative
- Pemphigus
- Haemoglobin decreased
- Hand deformity
- Haematochezia
- Glossodynia
- Inappropriate schedule of product administration
- Drug abuse
- Toxicity to various agents
- Weight decreased
- Pericarditis
Drug interactions
- dolutegravir
- enoxacin
- levodopa
- levofloxacin
- levothyroxine sodium
- lomefloxacin
- minocycline
- moxifloxacin
- mycophenolate mofetil
- norfloxacin
- ofloxacin
Key clinical trials
- Treatment of Hemochromatosis (PHASE2)
- Bevacizumab In Hereditary Hemorrhagic Telangiectasia (PHASE2)
- Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis (PHASE2)
- Adherence to Oral Therapies in Advanced Breast and Prostate Cancers (NA)
- Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients. (PHASE1)
- Iron and Immune Response to Vaccine (IRONMUM) (NA)
- Mechanisms Accounting for Unexplained Anemia in the Elderly (PHASE1)
- Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Elemental Iron (As Carbonyl Iron) CI brief — competitive landscape report
- Elemental Iron (As Carbonyl Iron) updates RSS · CI watch RSS
- Hippocration General Hospital portfolio CI